ArticleBMC surgery2025
Comparative clinical efficacy of hybrid EMR-hot avulsion versus thermal ablation for post-ESD residual margins (≤ 1 cm) in early gastric cancer: a preliminary study.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe management of positive lateral margins (pLMs) after endoscopic submucosal dissection (ESD) to treat early gastric cancer (EGC) remains controversial. We implemented a sequential therapeutic protocol for post-ESD pLM management; this protocol involved progressing from argon plasma coagulation (APC) and hot biopsy forceps-mediated avulsion to the hybrid endoscopic mucosal resection-hot avulsion (EMR-HA) technique. This study compared the outcomes of EMR-HA with those of thermal ablation (hot avulsion/APC) in the management of residual tumors measuring ≤ 1 cm with pLMs after gastric ESD, and both recurrence prevention and therapeutic efficacy were assessed.
methodsIn a retrospective cohort study (2015-2023) of 1,601 ESD procedures, 92 cases of pLMs with residual tumors that had maximum diameters ≤ 1 cm were analyzed. The therapeutic modalities were stratified as follows: hot avulsion (n = 25), APC (n = 41), and EMR-HA (n = 26). Statistical analyses were performed with one-way ANOVA, chi-square tests or Fisher's exact tests, as well as Kaplan‒Meier analysis.
resultsEMR-HA resulted in a lower recurrence rate of 11.5% (3/26; median follow-up of 63 months, IQR 41-66), showing superior efficacy to both hot avulsion (44% recurrence, 11/25; P = 0.013) and APC (36.6% recurrence, 15/41; P = 0.046). The thermal ablation cohort exhibited significantly shorter median recurrence intervals (hot avulsion: 20 months; APC: 18 months) than the negative lateral margin cohort (32 months; P < 0.05). Among the 42 patients who experienced recurrence, complete resection was achieved via re-ESD in 84.6% of patients (22/26), with a median disease-free survival time of 34.5 months (IQR 19.2-56).
conclusionsEMR-HA demonstrates clinically superior recurrence control compared to thermal ablation techniques, with extended therapeutic durability and reduced reintervention rates. The findings suggest its potential clinical utility as an endoscopic treatment option. Additionally, re-ESD provides reliable salvage for recurrent lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.